Page last updated: 2024-11-07

aldosterone and Coronavirus Infections

aldosterone has been researched along with Coronavirus Infections in 11 studies

Coronavirus Infections: Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's11 (100.00)2.80

Authors

AuthorsStudies
Bornstein, SR1
Dalan, R1
Hopkins, D1
Mingrone, G1
Boehm, BO1
Henry, BM1
Vikse, J1
Benoit, S1
Favaloro, EJ1
Lippi, G1
Alexandre, J1
Cracowski, JL1
Richard, V1
Bouhanick, B1
Mareev, YV1
Mareev, VY1
Pechère-Bertschi, A1
Ponte, B1
Wuerzner, G1
Curfman, G1
Dudoignon, E1
Moreno, N1
Deniau, B1
Coutrot, M1
Longer, R1
Amiot, Q1
Mebazaa, A1
Pirracchio, R1
Depret, F1
Legrand, M1
Culebras, E1
Hernández, F1
Otto, CM1
Young, MJ1
Clyne, CD1
Chapman, KE1
Mabillard, H2
Sayer, JA2

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Study of a 10-days Fenofibrate Treatment, or Until Discharge From Hospital, Among COVID-19 Infected Patients Requiring Hospitalization[NCT04661930]Phase 355 participants (Anticipated)Interventional2021-01-01Recruiting
Time of Recovery and Prognostic Factors of COVID-19 Pneumonia[NCT04324684]198 participants (Actual)Observational2020-03-31Completed
FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396]Phase 2701 participants (Actual)Interventional2020-08-18Completed
Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19[NCT05736900]200 participants (Actual)Interventional2020-09-10Completed
Laparoscopic Bariatric Surgery During Phase 2-3 Covid-19 Pandemic in Italy: a Multicenter, Prospective, Observational Study.[NCT04480034]1,600 participants (Anticipated)Observational2020-07-15Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

All-Cause Death

Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days

InterventionParticipants (Count of Participants)
Fenofibrate + Usual Care19
Placebo + Usual Care22

Exploratory Hierarchical Composite Endpoint

The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care5.03
Placebo + Usual Care5.03

Number of Days Alive and Out of the Hospital During the 30 Days Following Randomization

Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days

Interventiondays (Median)
Fenofibrate + Usual Care30
Placebo + Usual Care30

Number of Days Alive, Out of the Intensive Care Unit, Free of Mechanical Ventilation/Extracorporeal Membrane Oxygenation, or Maximal Available Respiratory Support in the 30 Days Following Randomization

Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days

Interventiondays (Mean)
Fenofibrate + Usual Care28.8
Placebo + Usual Care28.3

Primary Hierarchical Composite Endpoint

The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days

InterventionRanked Severity Score (Median)
Fenofibrate + Usual Care5.32
Placebo + Usual Care5.33

Secondary Hierarchical Composite Endpoint

The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care5.05
Placebo + Usual Care5.05

Seven-category Ordinal Scale

A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days

Interventionscore on a scale (Median)
Fenofibrate + Usual Care1
Placebo + Usual Care1

Reviews

4 reviews available for aldosterone and Coronavirus Infections

ArticleYear
Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis.
    Clinica chimica acta; international journal of clinical chemistry, 2020, Volume: 507

    Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Immunity, Innate; Inflammati

2020
Renin-angiotensin-aldosterone system and COVID-19 infection.
    Annales d'endocrinologie, 2020, Volume: 81, Issue:2-3

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-C

2020
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
    The Journal of endocrinology, 2020, Volume: 247, Issue:2

    Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Bet

2020
Electrolyte Disturbances in SARS-CoV-2 Infection.
    F1000Research, 2020, Volume: 9

    Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P

2020
Electrolyte Disturbances in SARS-CoV-2 Infection.
    F1000Research, 2020, Volume: 9

    Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P

2020
Electrolyte Disturbances in SARS-CoV-2 Infection.
    F1000Research, 2020, Volume: 9

    Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P

2020
Electrolyte Disturbances in SARS-CoV-2 Infection.
    F1000Research, 2020, Volume: 9

    Topics: Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Electrolytes; Humans; Hypokalemia; P

2020

Other Studies

7 other studies available for aldosterone and Coronavirus Infections

ArticleYear
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
Endocrine and metabolic link to coronavirus infection.
    Nature reviews. Endocrinology, 2020, Volume: 16, Issue:6

    Topics: Aldosterone; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID-19; Diabetes Mellitus, Type

2020
[Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers].
    Kardiologiia, 2020, Apr-08, Volume: 60, Issue:4

    Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin

2020
[Renin-angiotensin-aldosterone blockers and Covic-19 infection : friends or enemies ?]
    Revue medicale suisse, 2020, May-13, Volume: 16, Issue:693

    Topics: Aldosterone; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Angiotensins

2020
Renin-Angiotensin-Aldosterone Inhibitors and Susceptibility to and Severity of COVID-19.
    JAMA, 2020, 07-14, Volume: 324, Issue:2

    Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin

2020
Activation of the renin-angiotensin-aldosterone system is associated with Acute Kidney Injury in COVID-19.
    Anaesthesia, critical care & pain medicine, 2020, Volume: 39, Issue:4

    Topics: Acute Kidney Injury; Aged; Aldosterone; Betacoronavirus; Coronavirus Infections; COVID-19; Creatinin

2020
ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
    European heart journal, 2020, 06-01, Volume: 41, Issue:32

    Topics: Aldosterone; Angiotensins; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Heart Failure;

2020
Heartbeat: interaction of renin-angiotensin-aldosterone blocking drugs with COVID-19 disease susceptibility and severity.
    Heart (British Cardiac Society), 2020, Volume: 106, Issue:19

    Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensin

2020